On Invalid Date, Carisma Therapeutics (NASDAQ: CARM) reported Q4 2023 earnings per share (EPS) of -$0.48, up 93.71% year over year. Total Carisma Therapeutics earnings for the quarter were -$20.96 million. In the same quarter last year, Carisma Therapeutics's earnings per share (EPS) was -$7.63.
As of Q2 2024, Carisma Therapeutics's earnings has grown year over year. Carisma Therapeutics's earnings in the past year totalled -$86.88 million.
What is CARM's earnings date?
Carisma Therapeutics's earnings date is Invalid Date. Add CARM to your watchlist to be reminded of CARM's next earnings announcement.
What was CARM's revenue last quarter?
On Invalid Date, Carisma Therapeutics (NASDAQ: CARM) reported Q4 2023 revenue of $4.29 million up 14.96% year over year. In the same quarter last year, Carisma Therapeutics's revenue was $3.73 million.
What was CARM's revenue growth in the past year?
As of Q2 2024, Carisma Therapeutics's revenue has grown 51.71% year over year. This is 94.02 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Carisma Therapeutics's revenue in the past year totalled $14.92 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.